Genesis Biopharma’s Contego is an autologous cell therapy product indicated for the treatment for Stage IV metastatic melanoma.
Lonza Therapeutic Cell Solutions head David Smith said Lonza is pleased to be in partnership with Genesis Biopharma, and to bring expertise in large-scale autologous cell therapy production to the task of making Contego widely available to patients suffering from metastatic melanoma.
Lonza is a provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.